drugset / Trial / NCT04430179

Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis

NCT04430179

Phase 2 Active not recruiting 30 enrolled University of South Florida
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigators will investigate the efficacy of dupilumab in patients with severe eosinophilic CRSsNP who are resistant to the conventional treatment with intranasal corticosteroids and have significantly extensive disease involving more than 2 sinuses bilaterally in sinus CT scan and Lund-Mackay sinus (LMK) CT score \>=10 at baseline.

Timeline

Start
2020-12-17
Primary completion
2025-07
Completion
2025-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dupilumab Monoclonal antibody 300 mg Subcutaneous